Journal of Radiopharmaceuticals and Molecular Probes (대한방사성의약품학회지)

Korean Society of Radiopharmaceuticals and Molecular Probes (대한방사성의약품학회)
권호 표지
DOI QR코드

DOI QR Code

Development of radiotracer for polo-box domain of polo-like kinase 1

  • Ryu, Eun Kyoung (Research Center for Bioconvergence Analysis, Korea Basic Science Institute, University of Science and Technology)
  • Received : 2019.12.13
  • Accepted : 2019.12.28
  • Published : 2019.12.30
Download PDF
⟨ Previous Next ⟩

Abstract

Polo-like kinase 1 (Plk1) is crucial regulator of cell cycle progression during mitosis. It is known to highly overexpress in many different tumor types, and has been implicated as a potential antimitotic cancer target. The phosphopeptide, Pro-Leu-His-Ser-p-Thr (PLHSpT), was shown a high level of affinity and specificity for the polo-box domain (PBD) of Plk1. However, the peptide has the limitation of cell permeability. We designed the derivatives to enhance the limitation of PLHSpT using drug delivery system. In addition, we synthesized and evaluated its radiotracer for tumor diagnosis. This review discusses the derivative and radiotracer that are suitable for tumor treatment and diagnosis for PBD of Plk1.

Keywords

References

  1. Glover DM, IM Hagan, and AA Tavares, Polo-like kinases: a team that plays throughout mitosis. Genes Dev 1998; 12(24): p. 3777-87. https://doi.org/10.1101/gad.12.24.3777
  2. van de Weerdt BC and RH Medema, Polo-like kinases: a team in control of the division. Cell Cycle 2006; 5(8): p. 853-64. https://doi.org/10.4161/cc.5.8.2692
  3. Holtrich U, G Wolf, A Brauninger, T Karn, B Bohme, H Rubsamen-Waigmann, and K Strebhardt, Induction and down-regulation of PLK, a human serine/threonine kinase expressed in proliferating cells and tumors. Proc Natl Acad Sci U S A 1994; 91(5): p. 1736-40. https://doi.org/10.1073/pnas.91.5.1736
  4. Simizu S and H Osada, Mutations in the Plk gene lead to instability of Plk protein in human tumour cell lines. Nat Cell Biol 2000; 2(11): p. 852-4. https://doi.org/10.1038/35041102
  5. Lee KS, JE Park, YH Kang, TS Kim, and JK Bang, Mechanisms underlying Plk1 polo-box domain-mediated biological processes and their physiological significance. Mol Cells 2014; 37(4): p. 286-94. https://doi.org/10.14348/molcells.2014.0002
  6. McInnes C, M Mezna, and PM Fischer, Progress in the discovery of polo-like kinase inhibitors. Curr Top Med Chem 2005; 5(2): p. 181-97. https://doi.org/10.2174/1568026053507660
  7. Baby B, P Antony, W Al Halabi, Z Al Homedi, and R Vijayan, Structural insights into the polypharmacological activity of quercetin on serine/threonine kinases. Drug Des Devel Ther 2016; 10: p. 3109-3123. https://doi.org/10.2147/DDDT.S118423
  8. Guan R, P Tapang, JD Leverson, D Albert, VL Giranda, and Y Luo, Small interfering RNA-mediated Polo-like kinase 1 depletion preferentially reduces the survival of p53-defective, oncogenic transformed cells and inhibits tumor growth in animals. Cancer Res 2005; 65(7): p. 2698-704. https://doi.org/10.1158/0008-5472.CAN-04-2131
  9. Liu X, M Lei, and RL Erikson, Normal cells, but not cancer cells, survive severe Plk1 depletion. Mol Cell Biol 2006; 26(6): p. 2093-108. https://doi.org/10.1128/MCB.26.6.2093-2108.2006
  10. Yun SM, T Moulaei, D Lim, JK Bang, JE Park, SR Shenoy, F Liu, YH Kang, C Liao, NK Soung, S Lee, DY Yoon, Y Lim, DH Lee, A Otaka, E Appella, JB McMahon, MC Nicklaus, TR Burke, Jr., MB Yaffe, A Wlodawer, and KS Lee, Structural and functional analyses of minimal phosphopeptides targeting the polo-box domain of pololike kinase 1. Nat Struct Mol Biol 2009; 16(8): p. 876-82. https://doi.org/10.1038/nsmb.1628
  11. Cho K, X Wang, S Nie, ZG Chen, and DM Shin, Therapeutic nanoparticles for drug delivery in cancer. Clin Cancer Res 2008; 14(5): p. 1310-6. https://doi.org/10.1158/1078-0432.CCR-07-1441
  12. Danhier F, O Feron, and V Preat, To exploit the tumor microenvironment: Passive and active tumor targeting of nanocarriers for anti-cancer drug delivery. J Control Release 2010; 148(2): p. 135-46. https://doi.org/10.1016/j.jconrel.2010.08.027
  13. Torchilin V, Tumor delivery of macromolecular drugs based on the EPR effect. Adv Drug Deliv Rev 2011; 63(3): p. 131-5. https://doi.org/10.1016/j.addr.2010.03.011
  14. Gillies RJ, N Raghunand, ML Garcia-Martin, and RA Gatenby, pH imaging. A review of pH measurement methods and applications in cancers. IEEE Eng Med Biol Mag 2004; 23(5): p. 57-64.
  15. Khramtsov VV and RJ Gillies, Janus-faced tumor microenvironment and redox. Antioxid Redox Signal 2014; 21(5): p. 723-9. https://doi.org/10.1089/ars.2014.5864
  16. Vaupel P and A Mayer, Hypoxia in cancer: significance and impact on clinical outcome. Cancer Metastasis Rev 2007; 26(2): p. 225-39. https://doi.org/10.1007/s10555-007-9055-1
  17. Kim SM, S Yoon, N Choi, KS Hong, RN Murugan, G Cho, and EK Ryu, In vivo tumor imaging using polobox domain of polo-like kinase 1 targeted peptide. Biomaterials 2012; 33(29): p. 6915-25. https://doi.org/10.1016/j.biomaterials.2012.06.046
  18. Yang C, T Wu, Y Qi, and Z Zhang, Recent Advances in the Application of Vitamin E TPGS for Drug Delivery. Theranostics 2018; 8(2): p. 464-485. https://doi.org/10.7150/thno.22711
  19. Cao N and SS Feng, Doxorubicin conjugated to D-alphatocopheryl polyethylene glycol 1000 succinate (TPGS): conjugation chemistry, characterization, in vitro and in vivo evaluation. Biomaterials 2008; 29(28): p. 3856-65. https://doi.org/10.1016/j.biomaterials.2008.05.016
  20. Dietrich M, MG Traber, PF Jacques, CE Cross, Y Hu, and G Block, Does gamma-tocopherol play a role in the primary prevention of heart disease and cancer? A review. J Am Coll Nutr 2006; 25(4): p. 292-9. https://doi.org/10.1080/07315724.2006.10719538
  21. Yim MS, NK Soung, EH Han, JY Min, H Han, EJ Son, HN Kim, B Kim, JK Bang, and EK Ryu, Vitamin E-Conjugated Phosphopeptide Inhibitor of the Polo-Box Domain of Polo-Like Kinase 1. Mol Pharm 2019.